Comparative Pharmacology
Head-to-head clinical analysis: HISTAFED versus ZADITOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HISTAFED versus ZADITOR.
HISTAFED vs ZADITOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HISTAFED is a combination of pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa causing vasoconstriction, and triprolidine, a first-generation antihistamine that competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, thereby preventing histamine-mediated effects.
Selective histamine H1 receptor antagonist. Stabilizes mast cells, reducing release of histamine and other mediators of allergic response.
60 mg orally every 4 to 6 hours as needed; maximum 360 mg per day.
1 drop in each affected eye twice daily, approximately 6-8 hours apart.
None Documented
None Documented
3-4 hours for pseudoephedrine component; shorter in children (2-3 h), prolonged in renal impairment
Terminal elimination half-life is approximately 7 hours in adults, which supports twice-daily dosing for sustained ocular effects.
Renal (approximately 65% as unchanged drug and metabolites), biliary/fecal (35%)
Primarily renal excretion as unchanged drug (approximately 30-40% of dose) and biliary/fecal elimination of metabolites (60-70%).
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine